Revises provisions relating to health insurance coverage of prescription drugs. (BDR 57-1041)
Summary
SB354 revises Nevada insurance law to change how health plans cover prescription drugs used to prevent or treat HIV and hepatitis C. The bill requires a broad range of insurers and health coverage entities — including individual and group health insurers, health benefit plans, benefit contracts, hospital and medical services corporations, health maintenance organizations, and managed care organizations — to cover FDA-approved drugs for HIV prevention and for HIV or hepatitis C treatment, along with related laboratory testing and certain primary-care and pharmacist-delivered services. It also requires reimbursement parity for pharmacists, physician assistants, and advanced practice registered nurses providing covered HIV/hepatitis C services.
The bill’s main policy change is to prohibit most private health plans from using medical management techniques, including step therapy, to delay access to these covered drugs and services. It preserves an exception allowing the Public Employees’ Benefits Program and Medicaid-related managed care arrangements to continue using step therapy for these benefits. The bill also updates effective dates so the new requirements generally apply to policies and plans delivered, issued, or renewed on or after January 1, 2027, while allowing agencies to begin rulemaking and administrative preparation immediately upon passage.
Impact
SB354 would amend multiple sections of Nevada insurance law and related public employee health coverage provisions to make HIV and hepatitis C drug coverage more accessible and less subject to utilization controls in the private market. It voids conflicting plan terms, expands coverage obligations across several categories of insurers and health plans, and defines step therapy and other medical management techniques in statute. The bill also affects reimbursement rules for pharmacists, physician assistants, and advanced practice registered nurses, and it leaves public-sector plans and Medicaid managed care with authority to retain step therapy for these drugs.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears supportive of expanding access to HIV and hepatitis C treatment and prevention. The structure of the bill suggests a public-health-oriented approach aimed at reducing barriers to timely medication access, especially by limiting insurer-imposed utilization management. No opposing arguments, amendments in debate, or recorded roll-call votes were provided to indicate broader controversy in the available record.
Contention
The principal point of contention embedded in the bill is the treatment of step therapy. SB354 removes step therapy as an allowable medical management technique for most private plans, but expressly preserves it for the Public Employees’ Benefits Program and Medicaid managed care organizations. That carveout suggests a policy compromise between access advocates and payers concerned about cost control. Another likely area of debate is the bill’s impact on insurer utilization management and costs, since it requires coverage regardless of formulary placement and restricts common cost-containment tools such as prior authorization and drug tiering for these therapies.